9.C.21. The Lysophospholipid Transporter(s) across the Blood-Brain Barrier (LPLT-BBB) Family
The use of lysophospholipid (LPL) supplementation to prevent chronic and age-related diseases has been documented. Tsukahara et al. 2023 evaluated the transmembrane transport of LPL across rat and monkey blood-brain barrier (BBB) models. An in vitro monkey BBB model is required to elucidate the differences between rat and primate BBB-related data and to measure the permeability of LPLs being researched in relation to the human BBB. Based on previous experiments, porcine liver decomposition product-derived phospholipids (PEL) strongly inhibit alpha-synuclein (alpha-Syn) aggregation. The authors identified several candidates potentially relevant for the inhibition of alpha-Syn aggregation, such as LPC18:1, LPE18:1, and LPI18:0. Tsukahara et al. 2023 assessed the ability of these LPLs to pass through the in vitro rat and monkey BBB models. LPC18:1 showed high BBB permeability, LPI18:0 showed medium permeability, and the BBB permeation of LPE18:1 was negligible. These results suggest that LPC18:1 and LPI18:0 are functional food factors that can cross the BBB.